All In Biotech

Drug Trial Radar · NCT00074971

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

A Multi-center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Dec 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

58

Actual

Start

Oct 1999

Primary completion

Not stated

Study completion Dec 2004

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 25, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globatriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.

Conditions

  • Fabry Disease

Interventions

  • Fabrazyme (agalsidase beta)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and efficacy
  2. Morphologic assessment of GL-3 inclusions in the capillary endothelium (vasculature) of the kidney

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California San Fransisco

    San Francisco, California

  • Northwest Oncology & Hematology Associates

    Coral Springs, Florida

  • Children's Memorial Hospital

    Chicago, Illinois

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Fetal Diagnostic and Imaging Center

    Billings, Montana

  • University of New Mexico

    Albuquerque, New Mexico

  • Mount Sinai School of Medicine

    New York, New York

  • University of Rochester School of Medicine

    Rochester, New York

  • Hart Family Practice

    Hickory, North Carolina

  • Hematology/Oncology Associates of South Texas

    San Antonio, Texas

  • University of Washington School of Medicine

    Seattle, Washington

  • Hospital Edouard Herriot

    Lyon, France

  • Hospital Europeen Georges Pompidou

    Paris, France

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • University of Puerto Rico

    San Juan, Puerto Rico

  • National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Hope Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.